FyoniBio GmbH

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) ›

Areas of Activity ›

External ›

Collaborations Formycon AG

Fraunhoferstr. 15 82152 Martinsried/Planegg Germany Sabrina Müller +49-89-864-667-100 +49-89-864-667-110 sabrina.mueller@formycon.com www.formycon.com

LI Q

~170 2012

Biosimilar Development, COVID-19 Drug Development FYB201, Formycon’s Biosimilar Candidate to Lucentis® (ranibizumab), licensed out to Bioeq AG, a joint venture between Strüngmann Group and Polpharma Biologics. Commercialisation of FYB201 by Coherus BioSciences, Inc. in the United States of America, Teva Pharmaceutical Industries Ltd. in Europe and other territories and MS Pharma in Middle East and North Africa. FYB202, Formycon’s Biosimilar Candidate to Stelara® (ustekinumab), developed in a joint venture with Aristo Pharma GmbH, a company owned by the Strüngmann Group. FYB203, Formycon’s Biosimilar Candidate to Eylea® (aflibercept), licensed out to Klinge Biopharma GmbH, a company owned by the Strüngmann Group. FYB207, Formycon’s COVID-19 Drug in development with academic partners Prof. Dr Ulrike Protzer, Chair of Virology, and Prof. Dr Johannes Buchner, Chair of Biotechnology, Technical University of Munich. Licensed out to SCG Cell Therapy Pte Ltd for Asia-Pacific-Region (except Japan).

Who we are:

Formycon is an expert company for the development of high-quality biopharmaceuticals, especially biosimilar medicines. The company’s pipeline contains three late-stage biosimilars, one preclinical biosimilar and an innovative COVID-19 drug.

Biosimilars – Medicines for the Future

A biosimilar medicine is a biological medicine highly similar to another already approved biological medicine (the ‘reference medicine’). Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines.

Through their proven efficacy, cost efficiency, and high standard of quality, biosimilar medicines are already making a major contribution towards improving patient access to essential medical treatments. Thereby biosimilars help patients around the world and also help to ease the financial strains on the world’s healthcare systems.

What we do:

Formycon develops biosimilars for the rapidly growing disease areas of ophthalmology and immunology as well as for other key chronic diseases. Formycon covers all stages of biopharmaceutical development from analytics and cell line development to preclinical and clinical studies, all the way through to the preparation of regulatory submission documents.

We develop biosimilar medicines to meet the high standards of the world’s most regulated markets: European Union, United States, Canada, Japan, and Australia.

Our Expertise:

Our unique advantage lies in the vast expertise of our international scientists, our management, and our board members. Through their long and distinguished careers, these scientific and business professionals have already, in their past work, successfully brought the world’s first biosimilars to market and bring comprehensive experience and expertise spanning all stages of drug development – from market analysis and protein analytics, to the development of production processes, to clinical trials and the regulatory approval process.

Innovative COVID-19 Drug

Based on extensive experience in biopharmaceutical drug development, Formycon is also working on the development of a COVID-19 drug: with FYB207, Formycon is developing an efficient antiviral SARS-CoV-2 blocker based on a long-acting ACE2-immunoglobulin fusion protein.

SARS-CoV-2 and other corona viruses use the protein ACE2 on the surface of human cells as a portal of entry for respiratory infections. Formycon has therefore fused the human ACE2 protein with the constant part of human immunoglobulin to create an innovative COVID-19 drug (FYB207) that is protected against viral mutations, completely prevents cell infection in vitro, and can potentially be used against all coronaviruses that use ACE2 as a portal of entry for cell infection.